Treatment of Antisocial Personality Disorder
The evidence for treating antisocial personality disorder (ASPD) is extremely limited, with no established evidence-based treatments available, but cognitive behavioral therapy (CBT) combined with structured residential or intensive outpatient settings offers the most reasonable approach based on available data. 1, 2
Critical Context About the Evidence Base
The treatment landscape for ASPD is notably weak compared to other psychiatric conditions:
- No pharmacological interventions have demonstrated efficacy for core ASPD symptoms, with all available medication studies showing no evidence of benefit for aggression, social functioning, or global functioning 3
- Psychological interventions show minimal and inconsistent effects, with most studies failing to demonstrate meaningful changes in antisocial behavior 1
- The certainty of all available evidence is rated as very low, meaning we have minimal confidence in reported effect estimates 1, 3
- Most research excluded participants based on ASPD diagnosis, instead focusing on substance abuse populations where ASPD was comorbid 1, 3
Recommended Treatment Approach
Initial Treatment Setting
Treatment must begin in a structured residential or intensive outpatient setting with active milieu therapy to have any realistic chance of success 2, 4:
- Outpatient-only approaches are insufficient for most patients with ASPD 4
- The structured environment provides external controls that patients with ASPD typically lack internally 2
- Active milieu therapy creates peer accountability and reduces manipulation of individual staff members 4
Psychotherapy: Cognitive Behavioral Therapy
CBT combined with treatment-as-usual (TAU) is the psychological intervention with the most supporting evidence, though effects remain modest 1:
- Structure CBT with 10-20 sessions over 3-6 months, with individual sessions lasting 60-90 minutes 1
- CBT should include: psychoeducation, behavioral goal setting, cognitive restructuring, problem-solving skills, and relapse prevention 5
- Individual therapy is preferred over group therapy when resources allow 6
One study (52 participants) found no difference between CBT + TAU versus TAU alone for physical aggression or social functioning at 12 months, highlighting the limited efficacy 1
Alternative Psychological Approaches
Schema therapy (ST) may improve social functioning in secure psychiatric settings, though evidence is extremely limited 1:
- One study (30 participants, 87% with ASPD) found ST reduced time to unsupervised leave by 137 days compared to TAU 1
- No difference was found for reconviction rates 1
- Evidence certainty is very low 1
Dialectical behavior therapy (DBT) may reduce self-harm behaviors in patients with ASPD, though this is based on a single small study with skewed data 1:
- DBT was originally developed for borderline personality disorder and combines CBT, skills training, and mindfulness 5
- The evidence for ASPD specifically is insufficient to make firm recommendations 1
Pharmacotherapy: Not Recommended
No medication has demonstrated efficacy for treating core ASPD symptoms 3:
- Phenytoin (300 mg/day): One study showed possible reduction in aggressive acts in male prisoners, but evidence is very low certainty and side effects were common 3
- Antidepressants (desipramine, nortriptyline): No evidence of benefit for social functioning or global state 3
- Dopamine agonists (bromocriptine, amantadine): No evidence of benefit, with bromocriptine causing severe flu-like symptoms and nausea leading to dropout 3
Medications should only be considered for treating specific comorbid conditions (depression, anxiety, substance use disorders), not for ASPD itself 3
Treatment Preconditions and Structure
Organizational Requirements
Effective treatment requires specific organizational structures 2:
- Multidisciplinary teams with expertise in personality disorders 2
- Clear protocols for managing manipulation, rule-breaking, and aggression 2
- Consistent boundaries and consequences across all staff members 4
- Regular team supervision to address countertransference reactions 4
Therapeutic Relationship Challenges
Clinicians must anticipate and manage intense countertransference 4:
- Patients with ASPD typically evoke strong negative reactions in treatment providers 4
- Manipulation of staff and treatment resistance are expected, not exceptional 4
- External structure and peer accountability reduce opportunities for splitting staff 2, 4
Comorbidity Management
Address comorbid substance use disorders and other psychiatric conditions as these are present in the majority of ASPD patients 5:
- Motivational interviewing and contingency management show some evidence for substance use reduction 5
- Integrated treatment addressing both ASPD and substance use is preferred over sequential treatment 5
- One study found contingency management + standard maintenance improved family/social functioning (ASI score reduction of 0.08 points) compared to standard maintenance alone 1
What NOT to Do
Avoid these common pitfalls:
- Do not rely on outpatient psychotherapy alone without structured environmental supports 4
- Do not prescribe medications targeting ASPD symptoms as none have demonstrated efficacy 3
- Do not expect rapid behavior change or use short-term interventions 2
- Do not work in isolation without team support and supervision 2, 4
Realistic Expectations
Maintain realistic treatment goals focused on harm reduction rather than personality transformation 1, 2:
- Reduction in frequency or severity of antisocial behaviors, not elimination 2
- Improved social functioning in specific domains 1
- Decreased substance use and associated harms 5
- No compelling evidence exists for fundamental change in antisocial behavior patterns 1
Critical Evidence Gap
The field urgently needs methodologically rigorous studies that recruit participants specifically for ASPD diagnosis and measure relevant outcomes including reconviction, violence, and social functioning 1, 3. Current evidence comes from unreplicated, single studies with significant methodological limitations 1, 3.